APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI Drug Design

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AI Drug Design Market Outlook and Growth Opportunities 2026

4 March 2026192 pages

Choose your research edition.

Industry ResearchAI Drug Design Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal AI Drug Design Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal AI Drug Design Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI Drug Design Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal AI Drug Design Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global AI Drug Design market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AI Drug Design is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AI Drug Design is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI Drug Design is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AI Drug Design market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AI Drug Design market include Exscientia, PathAI, Tempus, Aria Pharmaceuticals, BenchSci, Antidote, AiCure, Atomwise and Envisagenics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AI Drug Design market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AI Drug Design and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AI Drug Design revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI Drug Design market.

AI Drug Design Segment by Company

Exscientia

PathAI

Tempus

Aria Pharmaceuticals

BenchSci

Antidote

AiCure

Atomwise

Envisagenics

Sherlock

Deep Genomics

Benevolent

Iktos

AlmirallShare

AI Drug Design Segment by Type

Therapy Research

Design and Development

Others

AI Drug Design Segment by Application

Cancer

Cardiovascular Disease

Others

AI Drug Design Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AI Drug Design status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AI Drug Design key companies, revenue, market share, and recent developments.

3. To split the AI Drug Design breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AI Drug Design market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AI Drug Design significant trends, drivers, influence factors in global and regions.

6. To analyze AI Drug Design competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Drug Design market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI Drug Design and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Drug Design.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI Drug Design industry.

Chapter 3: Detailed analysis of AI Drug Design company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AI Drug Design in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AI Drug Design in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AI Drug Design Industry Trends Table 2. AI Drug Design Industry Drivers Table 3. AI Drug Design Industry Opportunities and Challenges Table 4. AI Drug Design Industry Restraints Table 5. Global AI Drug Design Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AI Drug Design Revenue Share by Company (2021-2026) Table 7. Global AI Drug Design Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AI Drug Design Key Company Manufacturing Base & Headquarters Table 9. Global AI Drug Design Company, Product Type & Application Table 10. Global AI Drug Design Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AI Drug Design by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Therapy Research Table 15. Significant Companies of Design and Development Table 16. Significant Companies of Others Table 17. Global AI Drug Design Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global AI Drug Design Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global AI Drug Design Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global AI Drug Design Sales Value Share by Type (2021-2026) Table 21. Global AI Drug Design Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Cancer Table 23. Significant Companies of Cardiovascular Disease Table 24. Significant Companies of Others Table 25. Global AI Drug Design Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global AI Drug Design Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global AI Drug Design Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global AI Drug Design Sales Value Share by Application (2021-2026) Table 29. Global AI Drug Design Sales Value Share by Application (2027-2032) Table 30. Global AI Drug Design Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global AI Drug Design Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global AI Drug Design Sales Value Share by Region (2021-2026) Table 33. Global AI Drug Design Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global AI Drug Design Sales Value Share by Region (2027-2032) Table 35. Global AI Drug Design Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global AI Drug Design Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global AI Drug Design Sales Value Market Share by Country (2021-2026) Table 38. Global AI Drug Design Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global AI Drug Design Sales Value Market Share by Country (2027-2032) Table 40. Exscientia Company Information Table 41. Exscientia Business Overview Table 42. Exscientia AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Exscientia AI Drug Design Product Portfolio Table 44. Exscientia Recent Development Table 45. PathAI Company Information Table 46. PathAI Business Overview Table 47. PathAI AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. PathAI AI Drug Design Product Portfolio Table 49. PathAI Recent Development Table 50. Tempus Company Information Table 51. Tempus Business Overview Table 52. Tempus AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Tempus AI Drug Design Product Portfolio Table 54. Tempus Recent Development Table 55. Aria Pharmaceuticals Company Information Table 56. Aria Pharmaceuticals Business Overview Table 57. Aria Pharmaceuticals AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Aria Pharmaceuticals AI Drug Design Product Portfolio Table 59. Aria Pharmaceuticals Recent Development Table 60. BenchSci Company Information Table 61. BenchSci Business Overview Table 62. BenchSci AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. BenchSci AI Drug Design Product Portfolio Table 64. BenchSci Recent Development Table 65. Antidote Company Information Table 66. Antidote Business Overview Table 67. Antidote AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Antidote AI Drug Design Product Portfolio Table 69. Antidote Recent Development Table 70. AiCure Company Information Table 71. AiCure Business Overview Table 72. AiCure AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. AiCure AI Drug Design Product Portfolio Table 74. AiCure Recent Development Table 75. Atomwise Company Information Table 76. Atomwise Business Overview Table 77. Atomwise AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Atomwise AI Drug Design Product Portfolio Table 79. Atomwise Recent Development Table 80. Envisagenics Company Information Table 81. Envisagenics Business Overview Table 82. Envisagenics AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Envisagenics AI Drug Design Product Portfolio Table 84. Envisagenics Recent Development Table 85. Sherlock Company Information Table 86. Sherlock Business Overview Table 87. Sherlock AI Drug Design Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sherlock AI Drug Design Product Portfolio Table 89. Sherlock Recent Development Table 90. Deep Genomics Company Information Table 91. Deep Genomics Business Overview Table 92. Deep Genomics AI Drug Design Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Deep Genomics AI Drug Design Product Portfolio Table 94. Deep Genomics Recent Development Table 95. Benevolent Company Information Table 96. Benevolent Business Overview Table 97. Benevolent AI Drug Design Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Benevolent AI Drug Design Product Portfolio Table 99. Benevolent Recent Development Table 100. Iktos Company Information Table 101. Iktos Business Overview Table 102. Iktos AI Drug Design Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Iktos AI Drug Design Product Portfolio Table 104. Iktos Recent Development Table 105. AlmirallShare Company Information Table 106. AlmirallShare Business Overview Table 107. AlmirallShare AI Drug Design Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. AlmirallShare AI Drug Design Product Portfolio Table 109. AlmirallShare Recent Development Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. AI Drug Design Product Image Figure 2. Global AI Drug Design Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI Drug Design Market Size (2021-2032) & (US$ Million) Figure 4. Global AI Drug Design Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Therapy Research Image Figure 8. Design and Development Image Figure 9. Others Image Figure 10. Global AI Drug Design Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global AI Drug Design Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global AI Drug Design Sales Value Share by Type (2021-2032) Figure 13. Cancer Image Figure 14. Cardiovascular Disease Image Figure 15. Others Image Figure 16. Global AI Drug Design Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global AI Drug Design Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global AI Drug Design Sales Value Share by Application (2021-2032) Figure 19. Global AI Drug Design Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global AI Drug Design Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America AI Drug Design Sales Value (2021-2032) & (US$ Million) Figure 22. North America AI Drug Design Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe AI Drug Design Sales Value (2021-2032) & (US$ Million) Figure 24. Europe AI Drug Design Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific AI Drug Design Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific AI Drug Design Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America AI Drug Design Sales Value (2021-2032) & (US$ Million) Figure 28. South America AI Drug Design Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa AI Drug Design Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa AI Drug Design Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt AI Drug Design Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt AI Drug Design Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt AI Drug Design Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Therapy Research
  • Design and Development
  • Others
Applications
  • Cancer
  • Cardiovascular Disease
  • Others
Companies covered
  • Exscientia
  • PathAI
  • Tempus
  • Aria Pharmaceuticals
  • BenchSci
  • Antidote
  • AiCure
  • Atomwise
  • Envisagenics
  • Sherlock
  • Deep Genomics
  • Benevolent
  • Iktos
  • AlmirallShare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AI Drug Design Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AI Drug Design Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AI Drug Design Market Dynamics
  1. 2.1 AI Drug Design Industry Trends
  2. 2.2 AI Drug Design Industry Drivers
  3. 2.3 AI Drug Design Industry Opportunities and Challenges
  4. 2.4 AI Drug Design Industry Restraints
3 AI Drug Design Market by Company
  1. 3.1 Global AI Drug Design Company Revenue Ranking in 2025
  2. 3.2 Global AI Drug Design Revenue by Company (2021-2026)
  3. 3.3 Global AI Drug Design Company Ranking (2024-2026)
  4. 3.4 Global AI Drug Design Company Manufacturing Base and Headquarters
  5. 3.5 Global AI Drug Design Company Product Type and Application
  6. 3.6 Global AI Drug Design Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AI Drug Design Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AI Drug Design Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AI Drug Design Market by Type
  1. 4.1 AI Drug Design Type Introduction
  2. 4.1.1 Therapy Research
  3. 4.1.2 Design and Development
  4. 4.1.3 Others
  5. 4.2 Global AI Drug Design Sales Value by Type
  6. 4.2.1 Global AI Drug Design Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global AI Drug Design Sales Value by Type (2021-2032)
  8. 4.2.3 Global AI Drug Design Sales Value Share by Type (2021-2032)
5 AI Drug Design Market by Application
  1. 5.1 AI Drug Design Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Cardiovascular Disease
  4. 5.1.3 Others
  5. 5.2 Global AI Drug Design Sales Value by Application
  6. 5.2.1 Global AI Drug Design Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global AI Drug Design Sales Value by Application (2021-2032)
  8. 5.2.3 Global AI Drug Design Sales Value Share by Application (2021-2032)
6 AI Drug Design Regional Value Analysis
  1. 6.1 Global AI Drug Design Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AI Drug Design Sales Value by Region (2021-2032)
  3. 6.2.1 Global AI Drug Design Sales Value by Region: 2021-2026
  4. 6.2.2 Global AI Drug Design Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AI Drug Design Sales Value (2021-2032)
  7. 6.3.2 North America AI Drug Design Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AI Drug Design Sales Value (2021-2032)
  10. 6.4.2 Europe AI Drug Design Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AI Drug Design Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AI Drug Design Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AI Drug Design Sales Value (2021-2032)
  16. 6.6.2 South America AI Drug Design Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AI Drug Design Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AI Drug Design Sales Value Share by Country, 2025 VS 2032
7 AI Drug Design Country-level Value Analysis
  1. 7.1 Global AI Drug Design Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AI Drug Design Sales Value by Country (2021-2032)
  3. 7.2.1 Global AI Drug Design Sales Value by Country (2021-2026)
  4. 7.2.2 Global AI Drug Design Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AI Drug Design Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AI Drug Design Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AI Drug Design Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AI Drug Design Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AI Drug Design Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AI Drug Design Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AI Drug Design Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AI Drug Design Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AI Drug Design Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AI Drug Design Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AI Drug Design Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AI Drug Design Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AI Drug Design Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AI Drug Design Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AI Drug Design Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AI Drug Design Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AI Drug Design Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AI Drug Design Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AI Drug Design Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AI Drug Design Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AI Drug Design Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AI Drug Design Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AI Drug Design Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AI Drug Design Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AI Drug Design Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AI Drug Design Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AI Drug Design Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AI Drug Design Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AI Drug Design Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AI Drug Design Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AI Drug Design Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AI Drug Design Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AI Drug Design Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AI Drug Design Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AI Drug Design Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AI Drug Design Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AI Drug Design Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AI Drug Design Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AI Drug Design Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AI Drug Design Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AI Drug Design Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AI Drug Design Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AI Drug Design Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AI Drug Design Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AI Drug Design Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AI Drug Design Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AI Drug Design Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AI Drug Design Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AI Drug Design Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AI Drug Design Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AI Drug Design Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AI Drug Design Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AI Drug Design Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AI Drug Design Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AI Drug Design Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AI Drug Design Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AI Drug Design Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AI Drug Design Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AI Drug Design Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AI Drug Design Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AI Drug Design Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AI Drug Design Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AI Drug Design Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AI Drug Design Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AI Drug Design Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AI Drug Design Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AI Drug Design Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AI Drug Design Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AI Drug Design Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AI Drug Design Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AI Drug Design Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AI Drug Design Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AI Drug Design Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AI Drug Design Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AI Drug Design Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AI Drug Design Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AI Drug Design Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AI Drug Design Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AI Drug Design Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AI Drug Design Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AI Drug Design Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AI Drug Design Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AI Drug Design Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AI Drug Design Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Exscientia
  2. 8.1.1 Exscientia Company Information
  3. 8.1.2 Exscientia Business Overview
  4. 8.1.3 Exscientia AI Drug Design Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Exscientia AI Drug Design Product Portfolio
  6. 8.1.5 Exscientia Recent Developments
  7. 8.2 PathAI
  8. 8.2.1 PathAI Company Information
  9. 8.2.2 PathAI Business Overview
  10. 8.2.3 PathAI AI Drug Design Revenue and Gross Margin (2021-2026)
  11. 8.2.4 PathAI AI Drug Design Product Portfolio
  12. 8.2.5 PathAI Recent Developments
  13. 8.3 Tempus
  14. 8.3.1 Tempus Company Information
  15. 8.3.2 Tempus Business Overview
  16. 8.3.3 Tempus AI Drug Design Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tempus AI Drug Design Product Portfolio
  18. 8.3.5 Tempus Recent Developments
  19. 8.4 Aria Pharmaceuticals
  20. 8.4.1 Aria Pharmaceuticals Company Information
  21. 8.4.2 Aria Pharmaceuticals Business Overview
  22. 8.4.3 Aria Pharmaceuticals AI Drug Design Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Aria Pharmaceuticals AI Drug Design Product Portfolio
  24. 8.4.5 Aria Pharmaceuticals Recent Developments
  25. 8.5 BenchSci
  26. 8.5.1 BenchSci Company Information
  27. 8.5.2 BenchSci Business Overview
  28. 8.5.3 BenchSci AI Drug Design Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BenchSci AI Drug Design Product Portfolio
  30. 8.5.5 BenchSci Recent Developments
  31. 8.6 Antidote
  32. 8.6.1 Antidote Company Information
  33. 8.6.2 Antidote Business Overview
  34. 8.6.3 Antidote AI Drug Design Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Antidote AI Drug Design Product Portfolio
  36. 8.6.5 Antidote Recent Developments
  37. 8.7 AiCure
  38. 8.7.1 AiCure Company Information
  39. 8.7.2 AiCure Business Overview
  40. 8.7.3 AiCure AI Drug Design Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AiCure AI Drug Design Product Portfolio
  42. 8.7.5 AiCure Recent Developments
  43. 8.8 Atomwise
  44. 8.8.1 Atomwise Company Information
  45. 8.8.2 Atomwise Business Overview
  46. 8.8.3 Atomwise AI Drug Design Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Atomwise AI Drug Design Product Portfolio
  48. 8.8.5 Atomwise Recent Developments
  49. 8.9 Envisagenics
  50. 8.9.1 Envisagenics Company Information
  51. 8.9.2 Envisagenics Business Overview
  52. 8.9.3 Envisagenics AI Drug Design Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Envisagenics AI Drug Design Product Portfolio
  54. 8.9.5 Envisagenics Recent Developments
  55. 8.10 Sherlock
  56. 8.10.1 Sherlock Company Information
  57. 8.10.2 Sherlock Business Overview
  58. 8.10.3 Sherlock AI Drug Design Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sherlock AI Drug Design Product Portfolio
  60. 8.10.5 Sherlock Recent Developments
  61. 8.11 Deep Genomics
  62. 8.11.1 Deep Genomics Company Information
  63. 8.11.2 Deep Genomics Business Overview
  64. 8.11.3 Deep Genomics AI Drug Design Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Deep Genomics AI Drug Design Product Portfolio
  66. 8.11.5 Deep Genomics Recent Developments
  67. 8.12 Benevolent
  68. 8.12.1 Benevolent Company Information
  69. 8.12.2 Benevolent Business Overview
  70. 8.12.3 Benevolent AI Drug Design Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Benevolent AI Drug Design Product Portfolio
  72. 8.12.5 Benevolent Recent Developments
  73. 8.13 Iktos
  74. 8.13.1 Iktos Company Information
  75. 8.13.2 Iktos Business Overview
  76. 8.13.3 Iktos AI Drug Design Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Iktos AI Drug Design Product Portfolio
  78. 8.13.5 Iktos Recent Developments
  79. 8.14 AlmirallShare
  80. 8.14.1 AlmirallShare Company Information
  81. 8.14.2 AlmirallShare Business Overview
  82. 8.14.3 AlmirallShare AI Drug Design Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AlmirallShare AI Drug Design Product Portfolio
  84. 8.14.5 AlmirallShare Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst